CraigBReederMD

Oncology • Phoenix, AZ

Hematologic Oncology

Associate Professor of Medicine, Mayo Clinic College of Medicine and Science

Join to view full profile

Dr. Reeder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reeder's full profile

Already have an account?

Office
5777 E Mayo Blvd
Phoenix, AZ 85054
Phone+1 480-515-6296

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1981 - 1983
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1978 - 1981
Southern Illinois University School of MedicineClass of 1978

Certifications & Licensure

AZ State Medical License 1986 - 2025
CA State Medical License 1983 - 2025
MN State Medical License 1979 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top Doctors:Arizona State Castle Connolly, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Start of enrollment: 2003 Jul 01
Completed
Phase 3
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 1, Phase 2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2006 Jul 01
Completed
Phase 2
Zevalin-beam for Aggressive Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 3
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2007 Dec 01
Completed
Phase 2
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma Start of enrollment: 2008 Aug 25
Active, not recruiting
Phase 1, Phase 2
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Start of enrollment: 2008 Aug 01
Completed
Phase 2
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 2
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Start of enrollment: 2010 Mar 01
Completed
Phase 2
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Start of enrollment: 2011 Jan 10
Completed
Phase 1, Phase 2
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Jan 17
Completed
Phase 2
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Start of enrollment: 2012 Jan 31
Active, not recruiting
Phase 2
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant Start of enrollment: 2012 Dec 07
Completed
Phase 2
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Start of enrollment: 2013 Mar 06
Recruiting
Not Applicable
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) Start of enrollment: 2014 Mar 05
Completed
Phase 2
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) Start of enrollment: 2014 Mar 26
Completed
Phase 2
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia Start of enrollment: 2018 Mar 23
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation.
Karan Chohan, Jonas Paludo, Surendra Dasari, Patrizia Mondello, Joseph P Novak
Blood. 2024-09-19
MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis.
Karan Chohan, Jonas Paludo, Surendra Dasari, Patrizia Mondello, Joseph P Novak
Haematologica. 2024-05-01
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Muhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, Vivek Roy, Taimur Sher
Anti-Cancer Drugs. 2024-01-01

Journal Articles

Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal Lymphoma
Lisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood

Abstracts/Posters

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
Craig B. Reeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
Craig B. Reeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Phoenix Dermatologist & Oncologist Honored for Providing Collaborative Care to Patient with Rare CancerMarch 25th, 2020
Amyloidosis Support GroupsJuly 24th, 2019
Mayo Clinic Researchers Identify TherapyMarch 9th, 2017